News

The FDA approves Agilent's MMR IHC Panel, enhancing personalized colorectal cancer treatment by identifying patients for targeted immunotherapy options.

New combination therapy shows promising results for advanced non-small cell lung cancer, offering hope for patients with limited treatment options.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 diabetes compared to other treatments.

Mabwell's 7MW4911 receives FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising preclinical results.

A new study reveals personalized treatment strategies for HER2-negative breast cancer, optimizing antibody-drug conjugate sequencing based on tumor characteristics.

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating acute myeloid leukemia.

A groundbreaking study reveals ctDNA testing outperforms traditional imaging in predicting outcomes for patients with large B-cell lymphoma, enhancing treatment strategies.

FDA endorses bexmarilimab for higher-risk myelodysplastic syndromes, paving the way for accelerated approval and promising treatment options.

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high heterogeneity and gaps in melanoma-specific validation data.

A groundbreaking phase 3 study for lisaftoclax offers hope for first-line treatment of higher-risk myelodysplastic syndrome, addressing a critical medical need.

FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved treatment options for patients.

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options.

New research reveals how ctDNA testing transforms treatment for muscle-invasive bladder cancer, identifying patients who benefit from targeted immunotherapy.

Neoadjuvant immunotherapy combined with chemotherapy shows promising results in treating limited-stage small cell lung cancer, enhancing surgical outcomes and survival rates.

Discover the latest breakthroughs in oncology, including FDA approvals and innovative treatments reshaping cancer care for patients and clinicians alike.

A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

Pembrolizumab showed strong anti-tumor activity in patients with unresectable desmoplastic melanoma.

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its potential for unmet medical needs.

FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development and potential breakthrough treatment.

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ovarian cancer.

A promising allogeneic CAR T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments have failed.

New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, reducing treatment burden and side effects.

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous system involvement.

A multidisciplinary expert panel issued recommendations on the use of bronchoscopic biopsies in terms of safety and sample adequacy for comprehensive biomarker testing.

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, intermediate-risk cervical cancer.

The CAR-T treatment GLPG5101 received the FDA's RMAT designation by showing promising efficacy with rapid delivery and low toxicity in mantle cell lymphoma.

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, highlighting its potential as a treatment option.

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal cancer, particularly if they had strong T-cell responses.